Lutetium-177 Market and Pipeline Analysis–Forecast to 2026

Publishing Date : February, 2020
Report Code : HCPH0003
Price:
Single license $3,600
Site license $5,400
Global license $7,200


Note: The report would be dispatched after confirmation of payment
  • “Lutetium-177 Market and Pipeline Analysis–Forecast to 2026” gives comprehensive insights on the various Lu-177 based drugs being developed for the treatment of GEP-NET, prostate cancer and other diseases. The report covers marketed products details and also drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on  Lu-177 labeled monoclonal antibodies and peptides for various indications that are in clinical trials, FDA and CE approved products (Lutathera).
  • The report covers the patient population, treatment cost, total addressable market and penetration for GEP-NET and Prostate cancer. It covers list of nuclear reactors that have potential to produce Lu-177 both medium and high flux reactor with their locations all over the world. It also focuses on supply chain analysis and market dynamics (DROT) of Lu-177.
  • This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Lu-177 global market. The report also provide strategic insights on some of the molecules which will eventually be launched in the next few years.

 

  • Market Analysis
  • In market analysis section, global GEP-NET and Prostate cancer market are indicated along with the Lu-177 therapy market size, eligible patients pool, total addressable market (TAM), market penetration, opportunity and demand for Lu-177 isotope is forecasted from 2019 to 2026.
  • Lu-177 players and their production capacities
  • Lu-177 market dynamics.
  • Lu-177 related deals analysis.
  • Funding scenario in Lu-177 market
  • Global, N.A., Europe, APAC and RoW prevalence rates (GEP-NET & Prostate cancer).
  • Pipeline Analysis
  • Pipeline Analysis by molecule type
    • Monoclonal Antibodies labelled pipeline analysis
    • Peptide labelled pipeline analysis
  • Pipeline analysis by leading players & their molecule analysis
  • Key Players Analysis
    • The key player’s analysis section provides an in-depth understanding of various companies working on Lu-177 and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.
    • Global key players overview
    • Global key players Pipeline data (discovery, pre-clinical & clinical development)
    • Global key players deals (collaborations, partnership, licensing agreements, grants, funds)
  • 1     REPORT DESCRIPTION
  • 2     INTRODUCTION
  • 3     EXECUTIVE SUMMARY
  • 4     MARKET DYNAMICS (DROT)
  • 5     SUPPLY CHAIN ANALYSIS
    • 5.1     Direct
    • 5.2     Indirect
  • 6     DEALS
    • 6.1     Acquisition
    • 6.2     License Agreement
    • 6.3     Partnership
    • 6.4     Collaboration
  • 7     FUNDING SCENARIO
  • 8     MARKET DATA
    • 8.1     TAM and Penetration - GEP-NET (Region)
    • 8.2     TAM -Prostate Cancer (Region)
  • 9     ASSUMPTIONS
  • 10     PIPELINE ANALYSIS
    • 10.1     Development Stage
    • 10.2     Indications
    • 10.3     Major Players
    • 10.4     Molecule Type
  • 11     RIT BASED PIPELINE ANALYSIS
    • 11.1     By Phase
    • 11.2     By Indications
    • 11.3     Clinical trial update on Phase 3 and Phase 2b molecules
  • 12     PRRT BASED PIPELINE ANALYSIS
    • 12.1     By Phase
    • 12.2     By Indications
    • 12.3     Clinical trial update on Phase 3 molecules
  • 13     MAJOR PLAYERS
    • 13.1     Company Profiles
    • 13.2     Overview
    • 13.3     Pipeline
  • 14     MEDIUM FLUX REACTORS AND THEIR LOCATION
  • 15     HIGH FLUX REACTORS AND THEIR LOCATION
  • 16     SUPPLIERS AND ANNUAL ESTIMATED PRODUCTION OF Lu-177
  • 17     REFERENCES